Literature DB >> 17175470

Tuboovarian abscesses in postmenopausal women.

Sheng-Mou Hsiao1, Fon-Jou Hsieh, Yih-Ron Lien.   

Abstract

OBJECTIVE: To compare the clinical features of tuboovarian abscess (TOA) in pre- and postmenopausal women.
MATERIALS AND METHODS: Between January 1992 and December 2000, all patients with surgically documented TOA at National Taiwan University Hospital were enrolled into this retrospective study. Salient information with respect to the history, current illnesses, risk factors, physical findings, laboratory data, surgeries and postoperative complications was obtained from medical records.
RESULTS: Of 74 patients with TOA, nine were postmenopausal women. Compared with the premenopausal group, postmenopausal patients were significantly more likely to have contributing medical disorders (p < 0.001) and concomitant pelvic malignant tumors (p = 0.037).
CONCLUSION: Thorough investigation for concomitant pelvic malignant tumors and meticulous medical care should be provided for postmenopausal women with TOA.

Entities:  

Mesh:

Year:  2006        PMID: 17175470     DOI: 10.1016/S1028-4559(09)60231-X

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  3 in total

1.  Idiopathic pyometra and tubo-ovarian abscess in a postmenopausal patient treated conservatively.

Authors:  Maria Ntioudi; Katerina Vasiliadou; Parthena Charalampidou-Keremidou
Journal:  Ger Med Sci       Date:  2022-06-14

2.  Colorectal Carcinoma in the Background of Pelvic Inflammatory Disease.

Authors:  M Ammar Kalas; Sara Alhariri; Andrew Jonathen Ortega; Gian Marco Galura; Ihsan Al Bayati; Sarah Al Obaidi
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

Review 3.  Tubo-ovarian abscess with sepsis in a nonagenarian woman: a case report and literature review.

Authors:  Kuan-Yi Chen; Jen-Yu Tseng; Chih-Yu Yang
Journal:  BMC Womens Health       Date:  2019-06-19       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.